



Alere Opens New Diagnostics Manufacturing Facility in India

New Manesar factory to produce critical diagnostics for detection of Malaria, Dengue, HIV and other infectious diseases

Delhi, India, Aug. 1, 2016 – Alere Inc. (NYSE: ALR), a global leader in rapid diagnostics, today announced the opening of a state-of-the-art diagnostics manufacturing facility in Manesar, Haryana. The new factory will produce rapid tests for the detection of infectious diseases including Malaria, Dengue and HIV and export them across the Asia Pacific region, which is heavily impacted by these diseases.

The Manesar facility will initially produce approximately 150 million rapid diagnostic tests annually and will have the capacity to double production to more than 300 million tests over time. Globally, Alere manufactures more than 1.5 billion tests annually and works with governments, non-governmental organizations (NGOs) and other partners to make the Company's rapid diagnostic tests affordable and accessible for those who need them.

The 180,000 sq. ft. factory in Manesar will initially employ a staff of approximately 300 people.

Through establishment of the Manesar factory, Alere is making a significant investment in India's manufacturing industry, economy and people. The new facility supports the goals of Prime Minister Narendra Modi's "Make in India" initiative, which seeks to transform India into a global manufacturing hub. The expansion of India's medical device sector is a key component of that vision to foster economic growth.

"Alere believes in Prime Minister Modi's vision of 'Make in India,' and is committed to improving access to affordable rapid diagnostics in India and throughout the Asia Pacific region through this new world-class manufacturing facility," said Namal Nawana, Chief Executive Officer at Alere. "In particular, the Malaria tests manufactured in Manesar will help support the Government's goal of eradicating this deadly disease in India by 2030."

About Alere

Alere believes that when diagnosing and monitoring health conditions, **Knowing now matters.**™ Alere delivers reliable and actionable information by providing rapid diagnostic tests, enhancing clinical and economic healthcare outcomes globally. Headquartered in Waltham, Mass., Alere focuses on rapid diagnostics for cardiometabolic disease, infectious disease and toxicology. For more information on Alere, please visit www.alere.com.

###



Media Contact:

Jackie Lustig
pr@alere.com
781.314.4009

Investor Contact:

Julie Cunningham
ir@alere.com
858.805-2232